M. Fernández-Abad

Potent Cell-Cycle Inhibition and Upregulation of Immune Response with Abemaciclib and Anastrozole in neoMONARCH, Phase II Neoadjuvant Study in HR+/HER2− Breast Cancer

Chiun-Sheng Huang, D. Slamon, M. Press, 2019, Clinical Cancer Research.

Molecular effects of lapatinib in patients with HER2 positive ductal carcinoma in situ

M. Hidalgo, S. Perea, I. Calvo, 2014, Breast Cancer Research.

Abstract PD5-01: Final results of NeoMONARCH: A phase 2 neoadjuvant study of abemaciclib in postmenopausal women with hormone receptor positive (HR+), HER2 negative breast cancer (BC)

M. Press, M. Martín, E. Petru, 2018 .

Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: The DEBBRAH trial

S. Servitja, A. Llombart-Cussac, J. Cortés, 2022, Neuro-oncology.

Potent Cell-Cycle Inhibition and Upregulation of Immune Response with Abemaciclib and Anastrozole in neoMONARCH, Phase II Neoadjuvant Study in HR þ /HER2 (cid:2) Breast Cancer A C

D. Slamon, S. Hurvitz, S. Wijayawardana, 2019 .

Molecular effects of lapatinib in patients with HER2 positive ductal carcinoma in situ

M. Hidalgo, S. Perea, I. Calvo, 2014, Breast Cancer Research.